Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
PDF Mourns the Passing of Oliver Sacks
Sunday, August 30, 2015

The Parkinson’s Disease Foundation  (PDF) mourns the loss of neurologist and friend, Oliver Sacks, M.D., (pictured at left), who passed away on August 30th. 

The National Parkinson Foundation Welcomes New Board Member
Friday, August 21, 2015

MIAMI — The National Parkinson Foundation (NPF) announced the election of a new member to its Board of Directors: Dr. Guido Goldman.

The National Parkinson Foundation Launches New and Improved Parkinson.org
Monday, August 3, 2015

Premier website for the Parkinson's disease community

MIAMI — The National Parkinson Foundation announces today the official launch of a redesigned website, www.parkinson.org, devoted to increasing awareness and understanding of Parkinson's disease by offering free resources to people diagnosed with the disease and their families.

NPF Funds Community Research
Monday, June 29, 2015

The National Parkinson Foundation’s Moving Day® Fall 2014 Walks Fund Nearly $1 Million in Parkinson’s Programs

Community Grants Awarded in Atlanta, Boston, Chicago, Los Angeles, Miami and North Carolina

NPF Study Finds that Regular Exercise Can Slow Decline in Quality of Life
Wednesday, June 17, 2015

Data from the Parkinson’s Outcomes Project Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders

PDF Congratulates New NINDS Director Walter J. Koroshetz, M.D.
Tuesday, June 16, 2015

The Parkinson's Disease Foundation congratulates Walter J. Koroshetz, M.D., on being selected as the Director of the National Institute of Neurological Disorders and Stroke (NINDS). In this role, Dr. Koroshetz assumes oversight of a $1.6 billion budget for scientific research into neurological diseases, including Parkinson’s disease.

PDF Survey Finds Patient Input is Critical to Guiding Parkinson’s Research
Monday, June 15, 2015

Data Presented at 19th Annual International Parkinson and Movement Disorders Society Congress in San Diego, CA - Jun 15 2015

National Initiative to Improve the Quality of Life for People with Parkinson’s
Monday, June 1, 2015

The Edmond J. Safra National Parkinson’s Wellness Initiative Launches in Boston and Washington, D.C.

Connect.Parkinson Study Completes Enrollment
Friday, May 29, 2015

The National Parkinson Foundation Removes Barriers to Expert Parkinson’s Care Through Telemedicine

Afghanistan Veteran, PDF Champion to Complete Luxembourg IRONMAN for Parkinson’s Research on Saturday, June 20
Friday, May 29, 2015

US Army First Lieutenant Ashley Murray, a Piscataway, NJ, native, is running, biking and swimming to fight for a future without Parkinson’s disease. First Lt. Murray, an Afghanistan veteran who is currently stationed in Germany, will complete the Ergo IRONMAN 70.3 Luxembourg triathlon on Saturday, June 20 to raise funds for the Parkinson’s Disease Foundation (PDF).

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.